CALL SPRINTER OPEN END - GILEAD SCIENCES | Market Closed - Swiss Exchange 16:20:00 14/06/2024 BST | ||
| 0.46 CHF | +9.52% |
|
| Current month | +12.20% | ||
| 1 month | -23.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 0.46 | +9.52% |
| 13/06/24 | 0.42 | -2.33% |
| 12/06/24 | 0.43 | -2.27% |
| 10/06/24 | 0.44 | -2.22% |
Delayed Quote Swiss Exchange
Last update June 14, 2024 at 04:20 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Vontobel
|
| OGIAEV | |
| ISIN | CH0567309072 |
| Date issued | 10/09/2020 |
| Strike | 54.65 $ |
| Maturity | Unlimited |
| Parity | 20 : 1 |
| Emission price | 0.66 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 1.77 CHF |
|---|---|
| Lowest since issue | 0.32 CHF |
| Spread | 0.01 CHF |
| Spread % | 2.13% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
65.06
USD
Average target price
82.7
USD
Spread / Average Target
+27.11%
- Stock Market
- Certificates
- OGIAEV Certificat